Lilly gains FDA nod as first IL-17A antagonist for nr-axSpA

1 June 2020

The US Food and Drug Administration has approved a supplemental Biologics License Application (sBLA) for Taltz (ixekizumab) injection 80mg/mL for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation, submitted by US pharma major Eli Lilly (NYSE: LLY).

Another first-in-class milestone for the treatment, today's approval makes Taltz the first interleukin (IL)-17A antagonist to be approved by the FDA for nr-axSpA, says Lilly, whose shares were barely moved by the positive news.

Until this latest nod for Taltz, Novartis' (NOVN: VX) competing drug Cosentyx (secukinumab) has led the IL-17 class by total prescription numbers. Cosentyx, which generated first-quarter 2020 global sales of $930 million, gained European approval for or nr-axSpA in April this year and is under US and Japanese review for this indication. First-quarter sales of Taltz were $443.5 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK